Basilea Pharmaceutica’s Oncology Drug Candidate BAL101553 Demonstrates Broad Antitumor Activity In Treatment-Resistant Breast Cancer Models As Presented At American Association for Cancer Research

BASEL, Switzerland, April 7, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that new data demonstrating the broad activity of Basilea's novel oncology drug candidate BAL101553 in pre-clinical models of human breast cancer, including models resistant to standard agents used for the treatment of breast cancer, were presented at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California, USA.

Help employers find you! Check out all the jobs and post your resume.